[关键词]
[摘要]
目的 探讨辅酶Q10联合缬沙坦治疗慢性心力衰竭的临床效果。方法 选取2017年3月—2018年10月辽宁省人民医院收治的200例慢性心力衰竭患者,随机分为对照组和治疗组,每组各100例。对照组患者口服缬沙坦胶囊,1粒/次,1次/d。治疗组在对照组治疗基础上口服辅酶Q10胶囊,1粒/次,3次/d,饭后服用。两组均连续治疗4周。观察两组的临床疗效,比较两组治疗前后B型利钠肽(BNP)、心肌肌钙蛋白(cTn)I、血清相关指标、超声心动图相关指标、6 min步行距离(6MWD)的变化情况。结果 治疗后,对照组和治疗组的总有效率分别为84.0%、93.0%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血浆BNP、cTnI、生长分化因子-15(GDF-15)、半乳糖凝集素-3(Gal-3)、可溶性生长刺激表达基因2蛋白(sST2)水平均较治疗前显著下降,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组这些指标水平均显著低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组心输出量(CO)、左室射血分数(LVEF)、6MWD值较治疗前均显著升高,而左室舒张末期内径(LVEDD)、收缩末期内径(LVESD)值均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组CO、LVEF、6MWD值高于对照组,而LVEDD、LVESD值低于对照组,两组比较差异有统计学意义(P<0.05)。结论 辅酶Q10联合缬沙坦治疗慢性心力衰竭具有较好的临床疗效,能明显抑制患者心肌重构,减轻心肌损伤,提高心脏运动耐力,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical effect of coenzyme Q10 combined with valsartan in treatment of chronic heart failure. Methods 200 Patients with chronic heart failure in the People's Hospital of Liaoning Province from March 2017 to October 2018 were randomly divided into control (100 cases) and treatment (100 cases) groups. Patients in the control group were po administered with Valsartan Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Coenzyme Q10 Capsules on the basis of the control group, 1 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of BNP, cTnI, serum and echocardiographic indicators, and 6MWD in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 84.0% and 93.0%, and there were differences between two groups (P<0.05). After treatment, BNP, cTnI, GDF-15, Gal-3, and sST2 in the two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, these indicators in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, CO, LVEF, and 6MWD in the two groups were significantly increased, but LVEDD and LVESD were significantly decreased, and there were differences in the same group (P<0.05). After treatment, CO, LVEF, and 6MWD in the treatment group were higher than those in the control group, but LVEDD and LVESD were significantly lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Coenzyme Q10 combined with valsartan has significant effect in treatment of chronic heart failure, and can significantly inhibit myocardial remodeling, and also can reduce myocardial injury and improve cardiac exercise endurance, which has a certain clinical application value.
[中图分类号]
[基金项目]